

Cryptococcus gattii Emerges in Pacific Northwest

BY ROXANNA
GUILFORD-BLAKE

FROM THE 2010 INTERNATIONAL CONFERENCE
ON EMERGING INFECTIOUS DISEASES

ATLANTA — *Cryptococcus gattii*, a fungal pathogen previously found only in tropical and subtropical areas, is emerging as a serious infection in the U.S. Pacific Northwest, according to the Centers for Disease Control and Prevention.

It has infected at least 60 people and 52 animals in Washington, Oregon, Idaho, and California, according to Julie R. Harris, Ph.D., a CDC epidemiologist. This is “one of the most interesting emerging infectious diseases in the United States today,” she said.

In September 2009, the CDC and various organizations in the affected states began passive surveillance for human and veterinary cases in the Pacific North-

‘Patients might require prolonged therapy with antifungal drugs, or special procedures and follow-up that normally aren’t warranted with *C. neoformans* infections.’

west to understand the extent of the pathogen’s spread and its epidemiology.

Twenty cases were identified in 2009, and she expects that even more cases will be identified this year.

Of the 39 patients on which researchers have data, 89% were hospitalized; 33% died of or with the *C. gattii* infection, she said. The mean age of infected patients is 52 years (range, 15-95 years); *C. gattii* appears to affect men and women equally. It’s rarely a pediatric disease. Moreover, it appears to infect both immunocompetent and immunocompromised patients, most of whom were not infected with HIV.

The most common symptoms are cough, shortness of breath, headache, nausea and vomiting, fever, and weight loss. The patients developed pneumonia (57%), meningitis (44%), encephalitis (21%), and cryptococcomas in the lung (34%) and the brain (25%).

Emilio DeBess, D.M.V., of the Oregon Department of Human Services, noted that *C. gattii* spores appear to live in association with certain trees and the soil around those trees. Humans can become infected by inhalation of the airborne fungi. “As far as we know, there is no human-to-human or animal-to-human transmission,” he said.

Before 1999, reports of infection were generally limited to tropical and subtropical areas and were most prevalent in Australia. In 1999, it was identified in Vancouver Island, B.C., and then jumped to the mainland in 2004, and spread to the U.S. Pacific Northwest. Most cases are in Washington and Oregon, but reports of infection also have been identified in Idaho and California, Dr. DeBess said.

One explanation for the recent transmissions is that the spores are carried by trucks on the I-5 corridor, which stretches from British Columbia to San Diego. “There are a lot of theories out there. That’s the one we are working with at this point,” he said. “Marion County [Oregon] along the I-5 corridor is the Petri dish of *C. gattii*.”

Then again, Dr. DeBess acknowledged that “it’s hard to say” whether *C. gattii* is

truly spreading or if more cases are being identified as a result of more intense surveillance.

C. gattii may be underdiagnosed and, as a result, the mortality rate may be inflated, he added. Both he and Dr. Harris noted the U.S. mortality rate is higher than that reported in British Columbia. He hopes to improve surveillance and promote awareness among physicians and veterinarians.

One of the clinical challenges, Dr. Harris noted, is that most labs cannot distinguish between *Cryptococcus neoformans* and *C. gattii*.

“We want all physicians to be aware that this is a new possible etiology of cryptococcal infections in the United States, and if infected with *C. gattii*, their patients might require prolonged therapy with antifungal drugs, or special procedures and follow-up that normally

Easy to teach¹

- Can be used in 6 straightforward steps

Easy to use¹

- Only long-acting insulin pen in which dose can be set from 1 to 80 units in 1-unit steps, dialed both up and down
- Once opened, Lantus[®] SoloSTAR[®] can be used for up to 28 days and is not refrigerated

Easy to inject¹

- Dose cannot be dialed past the number of units left in the pen
- It is important to keep the injection button pressed all the way in and to **slowly count to 10 before withdrawing the needle from the skin**. After a full injection, the number in the dose window will return to zero. These steps help ensure that the full dose has been delivered
- To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose

Important Safety Information for Lantus[®]

Contraindications

Lantus[®] is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus[®] with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus[®] via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus[®], and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus[®] dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus[®] are injection site reaction, lipodystrophy, pruritus, and rash.

Indications and Usage for Lantus[®]

Lantus[®] is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus[®] should be administered once a day at the same time every day.

Important Limitations of Use: Lantus[®] is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Lantus[®] SoloSTAR[®] is a disposable prefilled insulin pen.

Please see brief summary of full prescribing information for Lantus[®] on the next page.

References: 1. Data on file, sanofi-aventis U.S. LLC. 2. Lantus Prescribing Information. September 2009.

aren't warranted with *C. neoformans* infections," she said in an interview.

"Although most patients either live in or have visited the Pacific Northwest, we would encourage all physicians to keep *Cryptococcus gattii* in mind when they see an atypical patient with cryptococcal infection, as we don't yet know the extent of the endemic area," she said.

Because *C. neoformans* is so much more common than *C. gattii*, at this point she is not suggesting submission and speciation of every *Cryptococcus* isolate. "However, for patients with suspected *C. gattii* infection, we encourage

clinicians to report the cases to their states and submit isolates as requested for further speciation," she said.

Risk factors are poorly defined at this point, she added. "We know anecdotally that many patients live in or near wooded areas or have occupations that involve contact with soil or wood, but we don't have a good group with which to compare these types of exposures. We do plan to conduct a study on this in the near future." ■

Disclosures: Dr. DeBess and Dr. Harris reported that they had no conflicts.

IMNG medjobs.com

Thinking about a change? Interested in relocating? Go where the jobs are ...
www.imngmedjobs.com

For patients with diabetes using an insulin vial and syringe

Take aim with the Lantus® SoloSTAR® pen

Delivers 50% more insulin units per prescription for the same co-pay as a vial and syringe on most insurance plans

Prefilled with Lantus®, the only 24-hour insulin approved exclusively for use once a day to help patients with diabetes aim toward glycemic control²

Once-Daily
24-HOUR
LANTUS® SoloSTAR®
insulin glargine [rDNA origin] injection
STARring the #1-prescribed insulin^a

^aBased on TRx data from IMS Health, NPA™ Monthly database, time period from May 2003 to March 2010.

sanofi aventis
Because health matters